Global parenteral nutrition market analysis and insights
The global Parenteral Nutrition market estimated at US$6.90 billion in the year 2022 is now projected to grow at a CAGR of 7.86% and reach US$11.72 billion by 2028. This growth is primarily driven by the rising incidence of chronic diseases and conditions such as cancer, gastrointestinal disorders, and malnutrition, which often necessitate the use of parenteral nutrition to ensure adequate nutrient intake. Additionally, the aging global population is contributing to the market expansion, as elderly individuals are more prone to illnesses that may require nutritional support through intravenous routes.
Furthermore, advancements in healthcare infrastructure and technology are playing a pivotal role in the growth of the parenteral nutrition market. The development of innovative formulations and delivery systems, coupled with improved manufacturing processes, is enhancing the safety and efficacy of parenteral nutrition products. As the healthcare industry continues to emphasize personalized medicine, tailored parenteral nutrition solutions are gaining prominence, catering to the unique nutritional needs of individual patients. Moreover, the increasing awareness about the benefits of parenteral nutrition among healthcare professionals and patients is likely to drive market growth.
Looking ahead, future growth opportunities in the parenteral nutrition market are anticipated to arise from the integration of digital health technologies, such as telemedicine and remote patient monitoring. These technologies can facilitate better patient management and adherence to parenteral nutrition regimens. Additionally, expanding healthcare access in emerging markets and ongoing research and development efforts to create more advanced and cost-effective parenteral nutrition solutions present promising avenues for market players. The intersection of nutrition science, biotechnology, and healthcare innovation is expected to unlock new possibilities, making the parenteral nutrition market a dynamic and evolving sector with substantial growth potential.
Parenteral nutrition regional market insights
North American parenteral nutrition market is expected to grow significantly over the forecast period 2022-2028. This growth can be attributed to the substantial investments in the healthcare sector by commercial companies and government agencies. Furthermore, the rising frequency of chronic conditions like cancer and malnutrition, as well as the existence of modern healthcare facilities and advantageous reimbursement policies in the region, have resulted in a high hospital admission rate, which has fueled strong product demand. United States contributed around 78% of the total North American parenteral nutrition market. It is estimated to have a market value of US$1.85 billion in the year 2022.
Asia Pacific parenteral nutrition market is anticipated to witness an upsurge owing to the rapid industrialization and urbanization in developing countries like China and India. Moreover, the market is being driven by high R&D expenditure by major players, combined with efforts to commercialize parenteral nutrition products at affordable prices. China is expected to dominate the Asia-Pacific market and reach a market size of US$2.29 billion by 2028.
Within Europe, Germany, France, Italy and the U.K. are the key countries responsible for the significant growth of the regional market. Germany is expected to grow at a fastest CAGR of 7.93% over the forecast period.
Meanwhile, the Middle East & Africa is expected to show limited growth due to the strong presence of under-developed countries in Africa who are still struggling to meet technology standards. However, any growth that the region experiences is expected to come from developing Middle Eastern nations such as Qatar, U.A.E, and Oman due to a similar growth pattern as the Asia Pacific.
Key players
Key players profiled in the report include Aculife Healthcare Private Limited; Allergan plc; Amanta Healthcare Ltd; B. Braun Melsungen AG; Baxter International Inc.; Fresenius KABI AG; Grifols International S.A.; Guangzhou Baiyunshan Mingxing Pharmaceutical Co. Ltd.; ICU Medical Inc.; Otsuka Pharmaceutical Factory Inc.; Pfizer Inc.; Sichuan Kelun Pharmaceutical Co. Ltd.; Sino-Swed Pharmaceutical Corp. Ltd., among others.
Competitive Landscape
October 10, 2023 – Baxter Korea, a global front-runner in the healthcare sector, has announced the launch of a revolutionary total parenteral nutrition (TPN) solution named Olimel N12E. The solution is designed specifically for critically ill patients, aiming to improve their survival rates by providing a high concentration of proteins and calories, essential for their recovery.
June 26, 2023 – Grifols, a global leader in plasma medicines, has started marketing XEMBIFY®, its 20% subcutaneous immunoglobulin, in Spain. This plasma medicine is indicated for treating primary immunodeficiencies (PID) and certain secondary immunodeficiencies (SID), which are expected to grow significantly in the coming years.
Parenteral nutrition market scope
- By type of nutrient
- Carbohydrates
- Amino acid
- Lipid emulsion
- Vitamins
- Minerals
- By parenteral therapy
- Total parenteral nutrition (TPN)
- Partial parenteral nutrition (PPN)
- By patient group
- Neonates and infants
- Children and adolescents
- Adults
- Elderly
- By end use
- Hospitals and clinics
- Oncology centers
- Geriatric care facilities
- Home care service providers
- Others
- By region
- North America
- South America
- Europe
- Asia Pacific
- Middle East and Africa
| Report Attribute | Details |
| No. of Pages | 238 |
| Published | October-2023 |
| Forecast Period | 2022-2028 |
| Estimated Market Size in 2022 | US$6.90 billion |
| Forecasted Market Size by 2028 | US$11.72 billion |
| CAGR | 7.86% |
| Regions Covered | North America, South America, Europe, Asia Pacific, Middle East and Africa |
| Companies Mentioned | Aculife Healthcare Private Limited; Allergan plc; Amanta Healthcare Ltd; B. Braun Melsungen AG; Baxter International Inc.; Fresenius KABI AG; Grifols International S.A.; Guangzhou Baiyunshan Mingxing Pharmaceutical Co. Ltd.; ICU Medical Inc.; Otsuka Pharmaceutical Factory Inc.; Pfizer Inc.; Sichuan Kelun Pharmaceutical Co. Ltd.; Sino-Swed Pharmaceutical Corp. Ltd., among others. |
The research report provides a comprehensive review of market trends (Technology, Product and Application analysis), market growth drivers, PEST Analysis (Political, Economic, Social and Technological Analysis) Market growth inhibitors, and strategic industry activities and SWOT Analysis of key players in the market. The report provides market estimates and forecast for geographic markets such as the North America (United States, Canada, Mexico and Rest of North America), South America (Brazil, Argentina Chile Colombia Peru Venezuela Ecuador and Rest of South America), Europe (Germany, France, U.K., Russia, Italy, Spain, Sweden, Netherlands, Poland, Austria, Belgium, Finland, Norway, Switzerland, Denmark, Czech Republic, Portugal and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Taiwan, India, Australia, Indonesia, Philippines, Malaysia and Rest of Asia-Pacific), Middle East (Iran, Turkey, Kuwait, UAE, Israel, Oman, Bahrain, Saudi Arabia, Qatar, Egypt and Rest of Middle East) & Africa.
Research Methodology
